Search

everythinglearnresearchcommunity

for

Search:↓

TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.

Five FDA-approved drugs may help block COVID-19 virus entry.

Chemotherapy-induced hair loss is a major concern, but various treatments show promise in preventing and reversing it.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Oral valganciclovir improved a patient's skin condition caused by immunosuppression.

Cyclosporine A slows down hair loss from chemotherapy in mice, while dexamethasone increases hair loss but speeds up regrowth.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Common dermatology drugs were considered but are controversial for COVID-19 treatment.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Nanotechnology offers promising new treatments for PCOS by reducing inflammation and oxidative stress.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.

Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Blocking the virus's entry into cells by targeting certain pathways could lead to early COVID-19 treatments.

A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.

Combining Cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata.

Cepharanthine shows promise as a COVID-19 treatment.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.

Cooling with antioxidants helps protect hair during chemotherapy.

Cepharanthine may help treat COVID-19 by targeting multiple pathways.

JAK inhibitors and combination therapies show promise for treating severe alopecia areata.